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Abstract  The objectives of this study were to investigate the suitability of magnesium aluminium silicate (MAS) 
(Veegum®) to control drug release of a model drug, theophylline, from tablet matrices. To this end, the performance 
of three commonly used fillers namely: lactose, microcrystalline cellulose (Avicel PH102; MCC), and pre-
gelatinized starch, Starch 1500 PGS), were evaluated against Veegum®. The physico-mechanical properties of the 
tablet matrices were studied along with dissolution studies to determine the effect of single or binary mixtures of the 
excipients on the drug release pattern. A DSC hydration methodology was also employed to characterize the states 
of water present in the tablet matrices and to determine any impact on drug release. Formulations containing MAS 
alone produced compacts with the lowest hardness (4.5 kp) whereas formulations containing MCC alone produced 
the hardest tablets (17.2 kp). Dissolution studies suggested that matrices containing MAS alone released the 
theophylline quickest as compared to lactose, MCC or PGS. It was difficult to establish a trend of the bound and free 
water states in the tablet matrices; however the formulation containing only MAS had the highest bound water at 
29 %. The results therefore show that theophylline does not interact with MAS. As such the dominant factor in 
controlling drug release using MAS requires interaction or intercalation with a cationic drug. In the absence of this 
however, other excipients can play a role in controlling drug release. 
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1. Introduction 
Polymers such as hydroxypropyl methylcellulose 
(HPMC) have been extensively used to sustain, modify 
and extend drug release in formulations [1-8]. With the 
aim of obtaining zero-order release kinetics and further 
modification of drug release, several mixtures of polymers 
have also been exploited [9,10,11,12]. Clays are used in 
pharmaceutical products as stabilising agents as well as 
suspending agents in topical preparations. Their large 
specific surface area, good adsorption, ion exchange 
properties and the ability to form drug-clay interactions 
makes clay an attractive option for drug release 
modulation [13]. Magnesium aluminium silicate (MAS) 
(Veegum®) is a mixture of montmorillonites (MMT) and 
saponites, which are natural clays. These clays have a 
layered structure where each layer is made from 
tetrahedral arranged silica atoms fused into an edge shared 
octahedral plane of either aluminium or magnesium 
hydroxide [14,15]. 
These clay systems have been used in combination with 
sodium alginate (SA) to assess and characterise their 
potential as a film former [16]; and in combination with 
gelatin to generate nanocomposites as a result of the 
interaction between their functional groups [17]. In a 
previous study, the use of MMT as a sustained release 
carrier for ibuprofen was assessed and it was observed that 
release of ibuprofen from the ibuprofen/MMT composites 
was steady and pH dependent [18]. Another study 
investigated the use of propranolol-MAS intercalated 
complexes as drug reservoirs in HPMC tablets [19]. They 
observed that the complex tablets prepared with 
propranolol-MAS complexes were harder than tablets 
made with just propranolol or a physical mixture. In 
addition, drug release from the complex tablets followed 
zero-order release kinetic, while drug release from the 
other tablets was by anomalous transport. This led to the 
conclusion that propranolol-MAS complexes can be used 
as drug reservoirs in modified release tablets. One of the 
objectives of this study is to incorporate theophylline into 
clay matrices and evaluate the effect of fillers such as 
MCC (Avicel PH102), lactose monohydrate and starch 
1500 on its release from these matrices. 
Water in hydrogel systems can exist in three 
structurally distinct forms, each possessing different 
physical properties [20]. Type I (freezing or free, bulk-like 
water) melts at the melting point of pure water (0 °C). 
Type II (freezing or bound water) can interact weakly with 
macromolecules and displays a lower melting point than 
pure water (< 0 °C). Type III (bound water) interacts 
strongly with hydrophilic and ionic groups of the polymer 
and shows non-freezing behaviour. During the initial 
stages of dissolution, water penetrates into the matrix and 
usually acts as non-freezing (bound) water [21]. 
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Subsequently, the water content of the matrix increases 
and freezable water is detected at levels that are related to 
drug release. Transport of solutes occurs mainly through 
the free water with a minimum being transferred through 
bound water. It was also claimed that bound water did not 
participate to any significant effect in the hydration 
process for hydrophilic polymeric gelatin gels and that the 
hydrolysis/water uptake rate depended mainly on the 
amount of free water present in the system [22]. Therefore, 
knowing the dynamics and state of water molecules in 
hydrogels enables a better understanding of the swelling 
process of hydrophilic matrices and the release of drugs 
from such systems [23]. As such, another objective of this 
study was to investigate the state of water in the clay 
matrices to determine if it relates to drug release. 
2. Materials and Methods 
2.1. Materials 
Veegum F® EP (MAS) (R. T. Vanderbilt), 
Theophylline (TCI chemicals), MCC (Avicel PH102; 
FMC Biopolymer), lactose monohydrate (D.M.V Fonterra 
Excipients), PGS (Colorcon) and HPMC Methocel™ 
K4M (Colorcon) were used in the tablet formulations 
(Table 1). 66.67 mg and 3.33 mg of HPMC and 
magnesium stearate respectively were included in each 
formulation. HPMC was used at a low concentration so 
the effects of the various fillers were not masked. 
2.2. Tableting 
Tablets, with quantities of excipients as per Table 1, 
were prepared. All the ingredients, except magnesium 
stearate, were blended in a tumble mixer (Turbular T2C, 
Switzerland) for 8 minutes. The magnesium stearate was 
added to these mixtures and the samples were blended for 
a further 2 minutes. The tablets were compressed using a 
single punch tableting machine (Model MTCM-1, Globe 
Pharma, US) at 2500 psi (9.87 kN). 
Tablet hardness in kp thickness and diameter in mm 
were measured using the PharmaTest mechanical strength 
tester. The average values of three formulations were 
calculated as well as the standard deviation. 
Table 1. Model clay matrices formulation 










B1 100 163.3 - - - 
B2 100 - 163.3 - - 
B3 100 - - 163.3 - 
B4 100 - - - 163.3 
B5 100 81.65 81.65 - - 
B6 100 81.65 - 81.65 - 
B7 100 81.65 - - 81.65 
B8 100 41.6 121.7 - - 
B9 100 41.6  121.7 - 
B10 100 41.6   121.7 
Note: Each formulation contained 66.67 mg and 3.33 mg of HPMC and 
magnesium stearate respectively 
2.3. Dissolution Studies  
In-vitro dissolution was obtained in a USP II (paddle) 
method (PharmaTest) to characterise the release of 
theopylline from the matrix tablets. Sinkers were used in 
order to prevent the tablet from floating. The amount of 
drug in each tablet used was equivalent to 100 mg of drug. 
The studies were performed at 100 rpm rotation speed in a 
900 ml vessel of release medium (deionised water) at a 
temperature of 37 ± 0.5 °C. Theophylline release was 
analysed by UV at a wavelength of 271 nm. These 
experiments were carried out in triplicate. 
2.4. Dissolution Parameters 
 The mean dissolution time (MDT) is the mean time for 
the drug to dissolve under in-vitro dissolution conditions. 
MDT is a model-independent method and is suitable for 
dosage forms having different mechanisms of drug release. 
This parameter helps to characterize the drug release 
profile and enables comparison of drug release rates from 
the various formulations [24,25] and is calculated using 

















∑  (1) 
where j = sample number; tj = midpoint of the jth time 
period (easily calculated with ((t + t-1)/2) and jM∆  = 
additional amount of drug dissolved between tj and t-1. 
The mean dissolution rate (MDR) can be calculated 










= ∆ ∆= ∑  (2) 
where n = number of dissolution sample times; t∆  = 
time at the midpoint between t and t-1 (easily calculated 
with [t + (t-1)/2]. 
The area under the dissolution curve up to the time, t, 
expressed as the percentage of the area of the rectangle is 
known as the dissolution efficiency (DE) of a 
pharmaceutical dosage form [26]. This is mathematically 











where, y  = the percentage of drug dissolved at time t. 
2.5. DSC Hydration 
Mini tablets of target weight of 25 mg were produced 
for all formulations. The mini tablets were produced using 
the single punch tableting machine (Model MTCM-1, 
Globe Pharma, US) at 2500 psi (9.87 kN). 
The mini tablets were hydrated using a previously 
reported method [27,28]. In brief, the mini tablets were 
hydrated using 25 mg purified water in the standard 
aluminium pans and then sealed with a lid. The pans were 
initially cooled down from room/ambient temperature 
(20 °C) to -30 °C at 55 °C/min so that any unbound water 
(free water) would freeze. The temperature was kept at -
30 °C to allow for equilibration and then the samples were 
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heated from -30 °C to 50 °C at 10 °C/min under nitrogen. 
The amount of free and bound water in the tablets was 
determined using the endotherm scanning of the melted 
free water. A reference standard for determining amount 
of bound water in the theophylline mini tablets using 
distilled water was prepared using 25 mg purified water in 
standard aluminium pans sealed with a lid processed 
similarly to the hydrated tablets. 
3. Results and Discussion 
3.1. Effect of fillers on the physico-mechanical 
properties of the tablets 
Table 2 shows the average thickness, diameter and 
hardness of the various formulations of theophylline. All 
formulations had relatively similar thickness (4.05 - 4.50 
mm) and diameters (10.04 - 10.13 mm). However, the 
hardness test results were varied. Formulations containing 
MCC produced the tablet with the highest strength (B3, 
B6 and B9). As MCC is used as an excipient in the 
formulation of direct compressed tablets to harden tablets, 
this was to be expected. The results suggest that increasing 
the quantity or concentration of MCC produces harder 
tablets. PGS is a combination of maize starch and free 
amylose. It is used as a flow-aid, disintegrant, lubricant 
and binder in the formulation of tablets in direct 
compression and wet granulation [29]. Formulations 
containing PGS produced the tablets with the lowest 
mechanical strength (B4, B7 and B10). What was 
interesting to note was that the formulations containing 
MAS alone produced the weakest tablets. It was observed 
that MAS reduced the strength of the tablets prepared with 
Avicel. 
Table 2. Physico-mechanical properties of the tablets 








B1 4.05±0.006 10.25±0.02 4.5±0.2 29.4±4.24 
B2 4.38±0.029 10.08±0.02 11.03±0.5 23.4±2.3 
B3 4.35±0.021 10.04±0.06 17.17±0.12 19.0±0.35 
B4 4.50±0.078 10.08±0.025 6.17±0.68 21.7±1.29 
B5 4.20±0.021 10.14±0.025 6.03±0.31 24.6±1.68 
B6 4.21±0.03 10.11±0.021 9.83±0.51 21.1±1.39 
B7 4.29±0.072 10.13±0.017 5.63±0.23 22.2±1.77 
B8 4.29±0.023 10.09±0.015 9.07±0.98 24.2±0.51 
B9 4.25±0.021 10.10±0.025 14.4±1.00 20.7±0.06 
B10 4.43±0.012 10.08±0.012 8.00±0.36 22.5±0.35 
3.2. MAS effect on theophylline release 
Figure 1, Figure 2, and Figure 3 show the influence of 
MAS on theophylline release from the tablets. Figure 1 
shows a comparison of 49 % MAS with formulations that 
had no MAS but 49 % lactose, 49 % MCC and 49 % PGS 
respectively. The tablet with the lowest hardness was 
formulation B1 which contained only 49 % MAS and this 
could be the reason why the DE of this formulation was 
high at 81.75 %. As such, when the tablet was immersed 
into the dissolution fluid, the water ingress weakened the 
already weak bonds causing the tablet to disintegrate and 
release the drug quickly; formulation B1 matrices released 
100 % of the theophylline after 270 min. B2, B3 and B4 
however were a lot more controlled and released 100 % 
drug release was observed after about 540 min. 
Theophylline is not ionised and there was no evidence of 
complex formation to retard the rate of drug release. 
Formulation B4, containing 49 % PGS, had a slow 
dissolution profile. In an attempt to increase the 
dissolution of a poorly soluble drug- ibuprofen using 
starch or sodium starch glycolate, Nokhodchi et al. [30] 
found higher concentrations of starch or sodium starch 
glycolate to have a detrimental effect on ibuprofen 
dissolution. They deduced that the presence of such high 
concentrations of starch around ibuprofen particles 
generates a very viscous solution around ibuprofen 
particles leading to slow penetration of dissolution media 
into the tablet hence poor dissolution. This may have been 
a contributory factor to the release pattern of B4 which 
also had the lowest DE value of 65.41 % (Table 3). 
According to the DE values, drug release was in the order 
B1 > B2 > B3 > B4 (Table 3). The formulations B5, B6 
and B7 contain 24.5 % MAS so in a one-to-one ratio with 
lactose, MCC or PGS respectively. Drug release patterns 
from these formulations were very similar to that shown in 
Figure 2, however, there were small increases in DE, 
showing that the drug release was slightly faster in this 
media. DE values for these formulations were lower 
(67.80 -70.86) as compared to B1 containing MAS alone 
(81.75) indicating the beneficial effects of the fillers added 
to the clay matrix. Figure 3 shows a comparison of B1 to 
B8, B9 and B10. The amount of MAS has been reduced to 
12.5 %. The DE values again follow the order B1 > B8 > 
B9 > B10 (Table 3). The results suggest formulation B10 
to have the slowest drug release of all the formulations 
tested indicating a possible synergistic effect between 
PGS and MAS at that concentration. 
Table 3. Dissolution parameters of clay tablet matrices 





B1 81.75 35.43 0.25 
B2 70.74 30.63 0.21 
B3 68.92 34.09 0.21 
B4 65.41 30.53 0.19 
B5 70.86 33.90 0.22 
B6 72.21 31.73 0.21 
B7 67.80 30.16 0.19 
B8 75.95 31.37 0.23 
B9 70.69 32.12 0.20 
B10 64.80 28.06 0.18 
 
Figure 1. Effect of MAS concentration on theophylline release 
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Figure 2. Effect of 24.5 % MAS concentration on theophylline release 
 
Figure 3. Effect of 12.5 % MAS concentration on theophylline release 
3.3. Lactose effect on theophylline release 
Figure 4 shows the influence of the inclusion of lactose 
on the release capacity of the MAS. B2, B5 and B8 
contain 49 %, 24.5 % and 36.5 % lactose respectively. 
Lactose is used as an excipient in tablet formulations 
because it compresses well due to its elastic nature. 
Lactose is a disaccharide sugar and this could be the 
reason behind its increased DE as compared to the other 
fillers used although its DE values were all lower than that 
of B1 (Table 3). The addition of MAS to B5 and B8 
resulted in an increase in the dissolution rate from 0.21 % 
min-1 to 0.22 % min-1 and 0.23 % min-1 respectively 
suggesting the inclusion of MAS could increase drug 
release from the compacts. 
 
Figure 4. Effect of lactose concentration on theophylline release 
3.4. MCC effect on theophylline release 
Initially B3 released the drug slowly (Figure 5). 
However, as time progressed the tablets released more of 
the drug and this resulted in a DE value of 68.92 %. From 
the table of physico-mechanical properties of excipients, 
tablets containing MCC seemed to be the hardest (B3 > 
B9 > B6). This can also impact drug release, leading to a 
delay in the ingress of water into the tablet. 
 
Figure 5. Effect of MCC concentration on theophylline release 
3.5. PGS effect on the theophylline release 
Figure 6 shows that an increase in the amount of PGS 
in formulations resulted in a general decrease in 
theophylline release. PGS is used as a disintegrant during 
the tablet manufacture process. When starch comes into 
contact with water it swells and causes bonds between 
particles in the tablet to weaken and then break up, leading 
to tablet disintegration, and thus drug release. However in 
this case, the high concentrations of starch may potentially 
have generated a very viscous solution around the matrix 
tablets leading to a slow penetration of dissolution media 
into the tablet hence, its relatively slower dissolution 
profiles as compared to B1. 
 
Figure 6. Effect of starch concentration on theophylline release 
3.6. DSC hydration 
The hydration values were determined at 10 min to 
coincide with the first sampling time in the release studies. 
The DSC scans obtained from the hydration studies were 
integrated to determine the average amount of bound 
water present in the tablet matrices (Table 2). In 
comparing the first four formulations, MAS as a single 
excipient binds more to water than the other three 
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excipients used (29 %). MCC as a single excipient 
however contained the lowest amount of bound water with 
a value of 19 %. Binary mixtures of the excipients in 
different concentrations as depicted in Table 1 from B5-10, 
renders different bound water percentages in the various 
tablet matrices with the highest of 25 % for B5 and the 
lowest 21 % for B9. It proved difficult in trying to 
establish a trend as was done in Asare-Addo et al. [27] 
where the percentage bound water was successfully used 
to explain drug release from theophylline HPMC tablet 
matrices. They however observed in a more recent 
publication [31] that this was dependant on the nature of 
drug used as this same methodology proved unsuccessful 
in explaining drug release for a very soluble cationic drug. 
This may be due to the nature of MAS and, as such, 
warrants further research. 
4. Conclusion 
Theophylline tablet matrices were produced and the 
influence of the fillers used was investigated. MAS at 
49 % with theophylline did not prolong the drug release as 
compared to the other tablet formulations and also 
produced the compacts with the lowest mechanical 
strength. The results generally showed that MAS does not 
contribute to sustaining the release of theophylline from 
its matrices. This may be due to the nature of the model 
drug used. DSC hydration showed the states of water in 
the hydrated compact but failed to make a link as to how 
the drug was released. The results therefore show that the 
dominant factor in controlling drug release is interaction 
or intercalation of the drug with the clay. This is usually 
by the use of cationic drugs. In the absence of this, other 
excipients can play a role in controlling drug release. 
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